Search
Nervgen Pharma Ord Shs
NGENAdd to Watchlist
2.150USD
-0.050-2.27%
Close 06/22, 16:00（ET）Quotes delayed by 15 min
174.13MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-22The current earnings forecast score of Nervgen Pharma Ord Shs is 8.00, ranking 164 out of 389 in the Biotechnology & Medical Research industry.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
10.671
Target Price
+385.06%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Nervgen Pharma Ord Shs
NGEN
8
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
How have Nervgen Pharma Ord ShsNGEN's recent earnings per share performed?
The market expectation was USD -0.02, while Nervgen Pharma Ord ShsNGEN's earnings per share (EPS) for the previous quarter was USD -0.27. EPS for the next quarter is expected at USD -0.08.
What is the analyst rating for Nervgen Pharma Ord Shs?
Based on the ratings of Nervgen Pharma Ord Shs's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
